Table 2:
Distribution of uremic symptoms in the MDRD study (“Total Group”) and the subset of patients with measured GFR (mGFR) < 20 ml/min/1.73 m2 (“mGFR<20 Subgroup”).
| Tota Group | mGFR<20 Subgroup | |||
|---|---|---|---|---|
| Symptom (and question phrasing) | Prevalence, N (%) | Symptom score (if symptomatic), median (IQR) | Prevalence, N (%) | Symptom score (if symptomatic), median (IQR) |
| Bad taste “A bad taste in your mouth?” | 134/695 (19.3%) | 7 (3, 20) | 52/214 (24.3%) | 10 (5, 30) |
| Loss of appetite “A loss of appetite?” | 96/695 (13.8%) | 6 (3, 15) | 42/214 (19.6%) | 5 (3, 15) |
| Nausea “Nausea or being sick to your stomach?” | 133/693 (19.2%) | 5 (2, 10) | 61/212 (28.8%) | 6 (2, 12) |
| Vomiting “Vomiting?” | 52/695 (7.5%) | 3 (1, 7) | 25/214 (11.7%) | 3 (2, 10) |
| Itching “Itching?” | 144/694 (20.7%) | 10 (4, 26) | 53/213 (24.9%) | 10 (3, 20) |
| Lack of pep and energy “Lack of pep and energy?” | 265/693 (38.2%) | 15 (5, 30) | 106/212 (50.0%) | 20 (6, 30) |
| Tiring easily “Tiring easily, weakness?” | 262/693 (37.8%) | 16 (5, 30) | 110/212 (51.9%) | 20 (7, 30) |
| Daytime sleepiness “Falling asleep during the day?” | 141/693 (20.3%) | 10 (3, 20) | 54/212 (25.5%) | 10 (3, 30) |
| Decreased alertness “Decreased alertness?” | 88/693 (12.7%) | 8 (4, 30) | 28/212 (13.2%) | 6 (4, 30) |
| Forgetfulness “Forgetfulness?” | 140/695 (20.1%) | 10 (3, 30) | 46/214 (21.5%) | 15 (4, 30) |
| Numbness/tingling “Numbness and tingling in your hands and feet?” | 131/694 (18.9%) | 10 (4, 30) | 40/213 (18.8%) | 8 (5, 20) |
For each symptom, the original phrasing of the question on the patient symptom form is included.